🇺🇸 FDA
Patent

US 10653743

Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N

granted A61KA61K31/54A61K38/08

Quick answer

US patent 10653743 (Methods for the treatment of depression and anxiety by a melanocortin 5 receptor antagonist, PG-20N) held by Arizona Board of Regents on Behalf of the University of Arizona expires Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arizona Board of Regents on Behalf of the University of Arizona
Grant date
Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 14 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/54, A61K38/08, A61K38/10, A61K38/12